The introduction of AR-pathway inhibitors for the treatment of CRPC has unfortunately increased the frequency of a highly aggressive, AR-indifferent prostate cancer known as t-NEPC  (Beltran et al.34). The gene discussed is AR; the disease is prostate carcinoma.